JP6518199B6 - Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 - Google Patents

Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 Download PDF

Info

Publication number
JP6518199B6
JP6518199B6 JP2015562400A JP2015562400A JP6518199B6 JP 6518199 B6 JP6518199 B6 JP 6518199B6 JP 2015562400 A JP2015562400 A JP 2015562400A JP 2015562400 A JP2015562400 A JP 2015562400A JP 6518199 B6 JP6518199 B6 JP 6518199B6
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
mica
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015562400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512223A (ja
JP6518199B2 (ja
JP2016512223A5 (OSRAM
Inventor
チェニー，イアン・ウェイン
Original Assignee
ノヴェロジックス・バイオテクノロジー，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴェロジックス・バイオテクノロジー，インコーポレーテッド filed Critical ノヴェロジックス・バイオテクノロジー，インコーポレーテッド
Publication of JP2016512223A publication Critical patent/JP2016512223A/ja
Publication of JP2016512223A5 publication Critical patent/JP2016512223A5/ja
Publication of JP6518199B2 publication Critical patent/JP6518199B2/ja
Application granted granted Critical
Publication of JP6518199B6 publication Critical patent/JP6518199B6/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015562400A 2013-03-15 2014-03-15 Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 Expired - Fee Related JP6518199B6 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361801329P 2013-03-15 2013-03-15
US61/801,329 2013-03-15
US201461940372P 2014-02-15 2014-02-15
US61/940,372 2014-02-15
PCT/IB2014/001157 WO2014140904A2 (en) 2013-03-15 2014-03-15 Antibodies to mica and micb proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019080239A Division JP2019194180A (ja) 2013-03-15 2019-04-19 Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体

Publications (4)

Publication Number Publication Date
JP2016512223A JP2016512223A (ja) 2016-04-25
JP2016512223A5 JP2016512223A5 (OSRAM) 2017-04-20
JP6518199B2 JP6518199B2 (ja) 2019-05-22
JP6518199B6 true JP6518199B6 (ja) 2019-06-12

Family

ID=51538216

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015562400A Expired - Fee Related JP6518199B6 (ja) 2013-03-15 2014-03-15 Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
JP2019080239A Pending JP2019194180A (ja) 2013-03-15 2019-04-19 Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019080239A Pending JP2019194180A (ja) 2013-03-15 2019-04-19 Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体

Country Status (6)

Country Link
US (2) US10851148B2 (OSRAM)
EP (1) EP2970490A4 (OSRAM)
JP (2) JP6518199B6 (OSRAM)
AU (1) AU2014229476B2 (OSRAM)
CA (1) CA2906356A1 (OSRAM)
WO (1) WO2014140904A2 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
WO2015179627A1 (en) * 2014-05-21 2015-11-26 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
TN2018000187A1 (en) * 2015-12-04 2019-10-04 Dana Farber Cancer Inst Inc Vaccination with mica/b alpha 3 domain for the treatment of cancer
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
JP2020502042A (ja) 2016-10-19 2020-01-23 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
CN107964041B (zh) * 2016-10-20 2023-08-01 中国科学院广州生物医药与健康研究院 高稳定性和高亲和力的dmic及其制法
US11555076B2 (en) * 2016-10-29 2023-01-17 Genentech, Inc. Anti-MIC antibodies and methods of use
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
WO2018141959A1 (en) 2017-02-06 2018-08-09 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
CA3089478A1 (en) * 2018-01-25 2019-08-01 Pdi Therapeutics, Inc. Mica/b antibodies and methods of use
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
IL280487B2 (en) * 2018-07-31 2025-07-01 Cullinan Mica Corp Anti-mica/b antibodies that block mica/b shedding and methods of use
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
CN113166762B (zh) 2018-12-21 2025-01-14 瓦莱里奥治疗公司 新的偶联核酸分子及其用途
WO2020214957A1 (en) * 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
CA3148318A1 (en) * 2019-08-23 2021-03-04 Jennifer D. Wu Materials and methods for activating antigen-specific t cell responses
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
EP4192876A1 (en) * 2020-08-10 2023-06-14 Innate Pharma Cell surface mica and micb detection using antibodies
CN112574311B (zh) * 2020-12-14 2022-03-25 广州康盛生物科技股份有限公司 双mic结合活性的抗体及其应用
WO2022235676A1 (en) * 2021-05-04 2022-11-10 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer
IL313439A (en) 2021-12-16 2024-08-01 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
CN119998318A (zh) * 2022-04-08 2025-05-13 D2M生物治疗有限公司 抗mica/b抗体及其用途
KR102783449B1 (ko) * 2022-06-15 2025-03-19 주식회사 셀리드 자연 살해 ｔ 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2275141A1 (en) 1996-10-29 1998-05-07 Thomas Spies Cell stress regulated human mhc class i gene
US20050265996A1 (en) 2004-04-30 2005-12-01 Biopheresis Technologies, Inc. Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
EP1451333B1 (en) 2001-10-04 2009-06-24 Immunex Corporation Ul16 binding protein 4
WO2003089616A2 (en) * 2002-04-22 2003-10-30 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
DE102004042894A1 (de) 2004-08-30 2006-03-02 Eberhard-Karls-Universität Tübingen Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen
WO2008036981A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Research, Inc. Methods for treating mica-related disorders
CA3011859A1 (en) 2007-04-23 2008-10-30 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by erp5
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
CA2747011C (en) 2008-12-18 2018-06-19 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
TWI408370B (zh) 2011-05-19 2013-09-11 Univ Chang Gung 胰臟癌之血清生物檢測標誌及其應用
US8753640B2 (en) * 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
EP3210625B1 (en) 2011-09-30 2019-08-28 Dana-Farber Cancer Institute, Inc. Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
BR112014019611A2 (pt) 2012-02-07 2017-06-27 Innate Pharma agentes de ligação mica
EP2626994B1 (en) 2012-02-08 2019-04-03 GE Oil & Gas UK Limited Supplying electrical power to subsea equipment
WO2014140884A2 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands

Also Published As

Publication number Publication date
EP2970490A4 (en) 2017-04-26
WO2014140904A3 (en) 2014-12-31
AU2014229476B2 (en) 2019-07-11
US20160046689A1 (en) 2016-02-18
JP2016512223A (ja) 2016-04-25
WO2014140904A2 (en) 2014-09-18
EP2970490A2 (en) 2016-01-20
JP6518199B2 (ja) 2019-05-22
AU2014229476A1 (en) 2015-10-01
JP2019194180A (ja) 2019-11-07
US20210040173A1 (en) 2021-02-11
US10851148B2 (en) 2020-12-01
CA2906356A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
JP6518199B6 (ja) Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
US11066471B2 (en) Antibodies to MICA and MICB proteins
JP6799101B2 (ja) クローディンを発現するガン疾患を処置するための剤
JP7080213B2 (ja) 新規抗ｐｄ－ｌ１抗体
US20250289880A1 (en) Use of anti-fam19a5 antibodies for treating cancers
TW202123926A (zh) 使用her3抗原結合分子的癌症之治療及預防
KR20210015902A (ko) Psma 결합제 및 이의 용도
CN104024276A (zh) Lsr抗体及其用于癌症治疗的用途
TW202003568A (zh) Vista抗原結合分子
TW201942136A (zh) Her3抗原結合分子
UA119673C2 (uk) Біспецифічне fc-діатіло, здатне імуноспецифічно зв'язуватися з епітопом pd-1 і з епітопом lag-3, та його застосування
JP7716623B2 (ja) 排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
TW200916482A (en) Bone morphogenetic protein (BMP)-binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and use of same
ES2290072T3 (es) Anticuerpos frente a la proteina semp1, metodos para su produccion y usos de los mismos.
US20220396632A1 (en) Anti-psgl-1 compositions and methods for modulating myeloid cell infalmmatory phenotypes and uses thereof
AU2018394255A1 (en) Bispecific antibody construct directed to MUC17 and CD3
JP2019526528A (ja) 抗ｔｎｆｒｓｆ２５抗体
US20220251233A1 (en) Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20220387417A1 (en) Pharmaceutical Combination and Use Thereof
RU2811431C2 (ru) Антитело против клаудина 18a2 и его применение
NZ751584B2 (en) Antibodies to mica and micb proteins
NZ751584A (en) Antibodies to mica and micb proteins
JP2023530997A (ja) Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体
TW202438531A (zh) 抗ccr8抗體及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190419

R150 Certificate of patent or registration of utility model

Ref document number: 6518199

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R150 Certificate of patent or registration of utility model

Ref document number: 6518199

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees